Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance

Recursion Pharmaceuticals IncTrade
Direxion Daily TSLA Bull 2X SharesTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while Direxion Daily TSLA Bull 2X Shares trades at $8.32. Which is the better fit depends on your goals.

RXRXTSLL
Market Cap
$1.78B
Sector
HealthLeveraged / Inverse
52-Week High
$6.79$23.03
52-Week Low
$2.84$6.74
Enterprise Value
$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Direxion Daily TSLA Bull 2X Shares

TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.11, up 5.6% today. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages. The ETF, which aims to deliver twice Tesla's daily returns, lacks fundamental metrics as it is a leveraged product. Recent news highlights its volatility and investor focus on Tesla's performance.

The outlook for TSLL is tied to Tesla's stock volatility, offering amplified gains but significant risks. Key opportunities include potential upside from Tesla's growth, while risks involve high volatility and decay from daily rebalancing. Investors should be cautious due to the leveraged structure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX

About Direxion Daily TSLA Bull 2X Shares

TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.

Read more on TSLL